
usd may pm et
summari global supplier over-the-counter over-the-count non-prescript health care product
gener pharmaceut
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
plc lift
target price ep
estim -- long-term forward
price-to-earnings averag due poor growth outlook
elev risk aris larg tax
assess disput drop
ep estim
ep vs
beat consensu sale
yoy driven yoy
declin consum america
revenu consum intern
segment grew sale yoy
return sale growth new product
launch larg declin
sale firm saw signific margin
contract across segment think
relat consolid pharmaci give
poor growth outlook neutral
share despit low valuat rel
risk assess reflect view produc
mani commodity-lik product limit abil
control price also see focu suppli
store-label over-the-counter product drag long-term growth
often perceiv lower qualiti
brand view think consum percept
qualiti import health care product
especi economi well shopper
better-posit opt brand-nam over-the-counter
product also see signific risk relat
on-going tax disput irish govern
could result tax liabil
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead global health care supplier develop manufactur
distribut over-the-count over-the-counter prescript pharmaceut nutrit product activ
pharmaceut ingredi api consum product world largest manufactur
over-the-counter pharmaceut product privat label store brand market store brand product contain
activ ingredi advertis brand lower cost consum store brand
retail sell product store anoth chosen brand name
consum health product consum product bussi gener total
revenu compris broad line over-the-counter store brand product compar qualiti
efficaci advertis brand product compani typic gener revenu contract
provid store-label product retail pharmaci supermarket mass merchandis
gener sam club amazon aldi petsmart petco cost retail store brand
product typic much lower compar nation advertis brand-nam product
retail therefor price store brand product compet nation brand product yet realiz
greater gross profit store-brand item
major consum product categori includ analges cough/cold/allergy/sinu medic
gastrointestin smoke cessat item exampl store brand analges acetaminophen
activ ingredi brand tylenol consum product also includ broad rang household
gener gener sement gener roughli total revenu focus
develop manufactur sale gener prescript pharmaceut primarili market
manufactur oper base israel gener product includ oral product cream
ointment lotion gel shampoo foam suppositori spray liquid suspens solut
well nasal spray oral liquid transderm product compani also manufactur market
brand prescript drug licens firm
gener segment primarili sell product sourc joint ventur jv establish last
sever year three major drug wholesal nation pharmaci chain three primari
sourc jv red oak combin wbad combin walgreen
claruson combin
increas purchas power garner major purchas jv one driver
signific price deflat mani gener drug sell calcul gener
segment sale declin precipit
major develop march sold tysabri royalti right royalti pharma
billion plu potenti payment royalti earn meet specifi
threshold think price low end note declin tysabri sale competit
multipl sclerosi market tysabri gener million million royalti
decemb report irish offic revenu commiss gave notic
compani owe tax total billion euro approxim billion relat transact
execut subsidiari pharma amount compar cash equival million
decemb result risk larg unfund liabil tax assess stand
claim incom relat transact appropri report trade incom tax
howev disput commiss claim transact treat gain
tax appeal assess payment due process complet
could take year
financi trend total revenu declin period
adjust pre-tax incom margin declin around due declin revenu
contract profit margin adjust ep declin earn
interest tax amort ebita cover interest expens
reason leverag level view
senior director
global oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
bullish sinc may technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
e-estim na-not avail nm-not meaning nr-not rank ur-und review prior fiscal year end jun
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv activ food
 drug administr fda
-- posit brand drug
maker repres lion share
sub-industri market cap also expect
stabil gener profit margin
competit appear moder
modest growth overal prescript
banner year brand drug
fda new drug approv
repres continu recent surg
approv shatter previou
record-high approv set
year dwarf approv
mani new drug littl
competit provid tailwind
brand drug sale addit
novel drug approv rare
diseas receiv fda orphan statu
mean receiv seven year competit
exclus indic think
provid boost long-term brand
side sub-industri
outlook earn growth gener maker
posit closer neutral fda gener
approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side remain gener
maker think exit start
impact gener approv
tick vs first materi
declin least six year also note
move averag gener
applic lead indic view
recent high march
think anoth sign mitig
competit help slow gener
deflat yoy februari
versu yoy worst deflat
month think moder gener
deflat allow stabil gener
profit margin year ahead
anoth boost gener maker
record year fda first-gener approv
first-gener typic enter market
materi lower price brand
counterpart temporari protect
gener competitor allow
quick market share gain accordingli
recent increas first-gener provid
revenu tailwind gener maker
bolster posit outlook
sub-industri expect continu
growth prescript volum year
ahead recent growth health-insur
popul driven solid
employ growth
view think gain continu
strong labor market pull peopl onto
employee-sponsor health plan
like seek fill prescript
also think wave babi boomer age
prime drug-util year support
long-term growth drug volum
drop
year-to-d march
pharma index rose gain
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
keep target price below-p
forward ep estim reflect view
compani like continu face challeng particularli relat recent
tysabri sale howev posit news spin-off
prescript pharmaceut busi sale focu
consum busi also see increas stabil recent manag
chang keep ep estim respect
trade near estim fair valu expect share outperform
broader market next month /jim corridor
et cfra lower opinion share compani plc
hold buy lower target price
below-p forward ep estim see
challeng consum busi particularli anim health unit
price eros prescript pharmaceut unit ep vs
estim lower ep estim
ep estim sale fell consum
fx benefit rose prescript pharmaceut sale fell
separ announc separ prescript
pharmaceut unit spin-off sale merger
prescript pharmaceut unit account sale
highest oper margin unit compar
consum healthcar unit /jeffrey loo cfa
et cfra keep hold opinion share perrigo compani plc
lift target price ep
estim -- long-term forward price-to-earnings averag due poor growth
outlook elev risk aris larg tax assess
disput drop ep estim
ep vs beat consensu sale
yoy driven yoy declin consum america
revenu consum intern segment respect
prescript segment grew sale yoy return sale growth
new product launch larg declin adjust pre-tax
incom fell yoy faster sale firm saw signific margin
contract across segment think relat consolid
pharmaci give custom greater purchas power poor
growth outlook neutral share despit low valuat rel
et cfra keep hold opinion share perrigo compani plc
lift target price ep
estim -- long-term forward price-to-earnings averag due elev risk
aris recent notic larg tax assess loss price power
lift ep estim start ep
vs miss consensu sale yoy
driven yoy sale declin over-the-counter health care busi
sale yoy drop sale gener prescript drug busi
product price pressur consolid
pharmaci led greater price power downstream custom
view e-commerc hurt store-brand over-the-counter sale see sign
trend slow either leav us poor long-term outlook
growth also signific tax liabil risk view relat
past tax assess irish govern challeng
pm et cfra keep hold opinion share perrigo compani plc
lower target price
ep estim long-term averag forward price-to-earnings due
elev risk see aris recent notic larg tax assess
maintain ep estim share around
today compani report irish offic revenu
commiss gave notic owe tax total euro relat
transact execut subsidiari pharma current cash equival
total believ incom relat transact
appropri report trade incom tax disput
commiss claim transact treat gain tax
appeal assess payment due
process complet could take year remain neutral
share due uncertainti around whether pay larg tax
lower target ep
estim long-term averag forward price-to-earnings expect
below-averag ep growth result challeng gener unit
drop ep estim
faster-than-expect deterior gener busi sale
yoy gross profit margin fell approxim bp worst perform
quarter gener segment revenu saw sale
declin yoy sustain downward trend sinc increas
competit custom consolid drive declin
announc august plan exit busi although
still remain unclear form exit take adjust pre-tax incom
first nine month yoy much reason
believ better point given weak sale outlook
margin pressur compani face /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
